Viscoelastic Testing in the Management of Adult Patients on Mechanical Circulatory Support Devices with Focus on Extracorporeal Membrane Oxygenation

Abstract

Thromboembolic and hemorrhagic complications continue to remain frequent complications that significantly impact the morbidity and mortality of patients implanted with mechanical circulatory support devices (MCSDs). The severe acute respiratory syndrome caused by coronavirus 2 (SARS-CoV-2) has resulted in a number of COVID-19 patients being supported by MCSDs, specifically extracorporeal membrane oxygenation (ECMO), which in turn has created a crucial need for rapid assessment of hemostatic status in these patients to avoid bleeding and thrombotic complications. Currently, conventional plasma-based coagulation assays such as prothrombin time and activated partial thromboplastin time (aPTT) are used to assess hemostasis, and the activated clotting time (ACT) and aPTT are the most common tests used to monitor heparin anticoagulation in patients on ECMO. Unfractionated heparin remains the mainstay anticoagulation therapy for patients on ECMO. Extracorporeal Life Support Organization (ELSO) offers little guidance on the subject but does state that each institution should create its internal anticoagulation protocols. Viscoelastic assays (VEAs) are increasingly recognized by ELSO and ECMO community for their potential to assess hemostatic derangements in patients implanted with MCSDs as well as guidance for appropriate hemostatic therapy. This review focuses on the evidence for the use of viscoelastic assays to assess overall hemostasis and to guide the treatment of adult patients connected to an ECMO circuit. Limitations of the use of conventional assays, ACT, and VEA are also discussed.

Keywords

mechanical circulatory support - ECMO - viscoelastic assays - SARS-CoV-2 - COVID-19 - heparin monitoring

Publikationsverlauf

Artikel online veröffentlicht:
15. September 2022

• References

• 1 Rihal CS, Naidu SS, Givertz MM. et al; Society for Cardiovascular Angiography and Interventions (SCAI), Heart Failure Society of America (HFSA), Society of Thoracic Surgeons (STS), American Heart Association (AHA), and American College of Cardiology (ACC). 2015 SCAI/ACC/HFSA/STS Clinical Expert Consensus Statement on the use of percutaneous mechanical circulatory support devices in cardiovascular care: endorsed by the American Heart Association, the Cardiological Society of India, and Sociedad Latino Americana de Cardiologia Intervencion; Affirmation of Value by the Canadian Association of Interventional Cardiology-Association Canadienne de Cardiologie d'intervention. J Am Coll Cardiol 2015; 65 (19) e7-e26
• 2 Cook JL, Colvin M, Francis GS. et al; American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Radiology and Intervention; and Council on Cardiovascular Surgery and Anesthesia. Recommendations for the use of mechanical circulatory support: ambulatory and community patient care: a scientific statement from the American Heart Association. Circulation 2017; 135 (25) e1145-e1158
• 3 Copeland J, Langford S, Giampietro J, Arancio J, Arabia F. Total artificial heart update. Surg Technol Int 2021; 39: sti39/1449
• 4 Thomas J, Kostousov V, Teruya J. Bleeding and thrombotic complications in the use of extracorporeal membrane oxygenation. Semin Thromb Hemost 2018; 44 (01) 20-29
• 5 Willers A, Arens J, Mariani S. et al. New trends, advantages and disadvantages in anticoagulation and coating methods used in extracorporeal life support devices. Membranes (Basel) 2021; 11 (08) 617
• 6 Doyle AJ, Hunt BJ. Current understanding of how extracorporeal membrane oxygenators activate haemostasis and other blood components. Front Med (Lausanne) 2018; 5: 352
• 7 Annich GM. ECMO Extracorporeal Cardiopulmonary Support in Critical Care, Red Book. 4th ed.. Ann Arbor: Extracorporeal Life Support Organization; 2012
• 8 Cartwright B, Bruce HM, Kershaw G. et al. Hemostasis, coagulation and thrombin in venoarterial and venovenous extracorporeal membrane oxygenation: the HECTIC study. Sci Rep 2021; 11 (01) 7975
• 9 Lequier LAG, Al-Ibraham O, Bembea M. et al. ELSO Anticoagulation Guideline. 2014 . Accessed July 28, 2022, at: https://www.elso.org/portals/0/files/elsoanticoagulationguideline8–2014-table-contents
• 10 Chlebowski MM, Baltagi S, Carlson M, Levy JH, Spinella PC. Clinical controversies in anticoagulation monitoring and antithrombin supplementation for ECMO. Crit Care 2020; 24 (01) 19
• 11 Giani M, Russotto V, Pozzi M. et al. Thromboelastometry, thromboelastography, and conventional tests to assess anticoagulation during extracorporeal support: a prospective observational study. ASAIO J 2021; 67 (02) 196-200
• 12 Rastan AJ, Lachmann N, Walther T. et al. Autopsy findings in patients on postcardiotomy extracorporeal membrane oxygenation (ECMO). Int J Artif Organs 2006; 29 (12) 1121-1131
• 13 Extracorporeal Life Support Organization. 2022 , Registry Statistic. Accessed July 28, 2022, at: https://www.elso.org/Registry/Statistics.aspx
• 14 Mazzeffi MA, Chow JH, Tanaka K. COVID-19 associated hypercoagulability: manifestations, mechanisms, and management. Shock 2021; 55 (04) 465-471
• 15 Hékimian G, Masi P, Lejeune M. et al. Extracorporeal membrane oxygenation induces early alterations in coagulation and fibrinolysis profiles in COVID-19 patients with acute respiratory distress syndrome. Thromb Haemost 2021; 121 (08) 1031-1042
• 16 Badulak J, Antonini MV, Stead CM. et al; ELSO COVID-19 Working Group Members. Extracorporeal membrane oxygenation for COVID-19: updated 2021 guidelines from the Extracorporeal Life Support Organization. ASAIO J 2021; 67 (05) 485-495
• 17 Marasco SF, Lukas G, McDonald M, McMillan J, Ihle B. Review of ECMO (extra corporeal membrane oxygenation) support in critically ill adult patients. Heart Lung Circ 2008; 17 (Suppl. 04) S41-S47
• 18 Bembea MM, Annich G, Rycus P, Oldenburg G, Berkowitz I, Pronovost P. Variability in anticoagulation management of patients on extracorporeal membrane oxygenation: an international survey. Pediatr Crit Care Med 2013; 14 (02) e77-e84
• 19 Esper SA, Levy JH, Waters JH, Welsby IJ. Extracorporeal membrane oxygenation in the adult: a review of anticoagulation monitoring and transfusion. Anesth Analg 2014; 118 (04) 731-743
• 20 Esper SA, Welsby IJ, Subramaniam K. et al. Adult extracorporeal membrane oxygenation: an international survey of transfusion and anticoagulation techniques. Vox Sang 2017; 112 (05) 443-452
• 21 Marlar RA, Clement B, Gausman J. Activated partial thromboplastin time monitoring of unfractionated heparin therapy: issues and recommendations. Semin Thromb Hemost 2017; 43 (03) 253-260
• 22 Potapov EV, Antonides C, Crespo-Leiro MG. et al. 2019 EACTS Expert Consensus on long-term mechanical circulatory support. Eur J Cardiothorac Surg 2019; 56 (02) 230-270
• 23 Eikelboom JW, Hirsh J. Monitoring unfractionated heparin with the aPTT: time for a fresh look. Thromb Haemost 2006; 96 (05) 547-552
• 24 Hutt Centeno E, Militello M, Gomes MP. Anti-Xa assays: What is their role today in antithrombotic therapy?. Cleve Clin J Med 2019; 86 (06) 417-425
• 25 Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972; 287 (07) 324-327
• 26 Chiu HM, Hirsh J, Yung WL, Regoeczi E, Gent M. Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis. Blood 1977; 49 (02) 171-184
• 27 Levine MN, Hirsh J, Gent M. et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994; 154 (01) 49-56
• 28 Olson JD, Arkin CF, Brandt JT. et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med 1998; 122 (09) 782-798
• 29 College of American Pathologists. 2007 Hematology and Coagulation Laboratory Accreditation Checklist. Accessed July 28, 2022, at: www.cap.org
• 30 McRae HL, Militello L, Refaai MA. Updates in anticoagulation therapy monitoring. Biomedicines 2021; 9 (03) 262
• 31 Samama MM, Contant G, Spiro TE. et al; Rivaroxaban Anti-Factor Xa Chromogenic Assay Field Trial Laboratories. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 2012; 107 (02) 379-387
• 32 Samama MM, Amiral J, Guinet C, Perzborn E, Depasse F. An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma. Thromb Haemost 2010; 104 (05) 1078-1079
• 33 Gehrie E, Laposata M. Test of the month: the chromogenic antifactor Xa assay. Am J Hematol 2012; 87 (02) 194-196
• 34 Cuker A, Raby A, Moffat KA, Flynn G, Crowther MA. Interlaboratory variation in heparin monitoring: lessons from the Quality Management Program of Ontario coagulation surveys. Thromb Haemost 2010; 104 (04) 837-844
• 35 Cuker A, Ptashkin B, Konkle BA. et al. Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin time. J Thromb Haemost 2009; 7 (01) 80-86
• 36 Teien AN, Lie M, Abildgaard U. Assay of heparin in plasma using a chromogenic substrate for activated factor X. Thromb Res 1976; 8 (03) 413-416
• 37 Vera-Aguilera J, Yousef H, Beltran-Melgarejo D. et al. Clinical scenarios for discordant anti-Xa. Adv Hematol 2016; 2016: 4054806
• 38 Macedo KA, Tatarian P, Eugenio KR. Influence of direct oral anticoagulants on anti-factor Xa measurements utilized for monitoring heparin. Ann Pharmacother 2018; 52 (02) 154-159
• 39 Faust AC, Kanyer D, Wittkowsky AK. Managing transitions from oral factor Xa inhibitors to unfractionated heparin infusions. Am J Health Syst Pharm 2016; 73 (24) 2037-2041
• 40 Green TP, Isham-Schopf B, Steinhorn RH, Smith C, Irmiter RJ. Whole blood activated clotting time in infants during extracorporeal membrane oxygenation. Crit Care Med 1990; 18 (05) 494-498
• 41 Nankervis CA, Preston TJ, Dysart KC. et al. Assessing heparin dosing in neonates on venoarterial extracorporeal membrane oxygenation. ASAIO J 2007; 53 (01) 111-114
• 42 Khaja WA, Bilen O, Lukner RB, Edwards R, Teruya J. Evaluation of heparin assay for coagulation management in newborns undergoing ECMO. Am J Clin Pathol 2010; 134 (06) 950-954
• 43 Bembea MM, Schwartz JM, Shah N. et al. Anticoagulation monitoring during pediatric extracorporeal membrane oxygenation. ASAIO J 2013; 59 (01) 63-68
• 44 Liveris A, Bello RA, Friedmann P. et al. Anti-factor Xa assay is a superior correlate of heparin dose than activated partial thromboplastin time or activated clotting time in pediatric extracorporeal membrane oxygenation. Pediatr Crit Care Med 2014; 15 (02) e72-e79
• 45 Atallah S, Liebl M, Fitousis K, Bostan F, Masud F. Evaluation of the activated clotting time and activated partial thromboplastin time for the monitoring of heparin in adult extracorporeal membrane oxygenation patients. Perfusion 2014; 29 (05) 456-461
• 46 Brown E, Clarke J, Edward KL, Giandinoto JA. Point-of-care testing of activated clotting time in the ICU: Is it relevant?. Br J Nurs 2016; 25 (11) 608-612
• 47 Hussein HM, Georgiadis AL, Qureshi AI. Point-of-care testing for anticoagulation monitoring in neuroendovascular procedures. AJNR Am J Neuroradiol 2012; 33 (07) 1211-1220
• 48 Kratz A, Van Cott EM. Activated clotting time: methods and clinical applications. Point of Care: J Near-Patient Testing Technol 2005; 2: 90-94
• 49 Dalbert S, Ganter MT, Furrer L, Klaghofer R, Zollinger A, Hofer CK. Effects of heparin, haemodilution and aprotinin on kaolin-based activated clotting time: in vitro comparison of two different point of care devices. Acta Anaesthesiol Scand 2006; 50 (04) 461-468
• 50 Lewandrowski EL, Van Cott EM, Gregory K, Jang IK, Lewandrowski KB. Clinical evaluation of the i-STAT kaolin activated clotting time (ACT) test in different clinical settings in a large academic urban medical center: comparison with the Medtronic ACT Plus. Am J Clin Pathol 2011; 135 (05) 741-748
• 51 Volod O, Bunch CM, Zackariya N. et al. Viscoelastic hemostatic assays: a primer on legacy and new generation devices. J Clin Med 2022; 11 (03) 860
• 52 Lakshmanan RS, Efremov V, O'Donnell JS, Killard AJ. Measurement of the viscoelastic properties of blood plasma clot formation in response to tissue factor concentration-dependent activation. Anal Bioanal Chem 2016; 408 (24) 6581-6588
• 53 Hartmann J, Murphy M, Dias JD. Viscoelastic hemostatic assays: moving from the laboratory to the site of care—a review of established and emerging technologies. Diagnostics (Basel) 2020; 10 (02) 118
• 54 Carll T, Wool GD. Basic principles of viscoelastic testing. Transfusion 2020; 60 (Suppl. 06) S1-S9
• 55 Hoffman M, Monroe III DM. A cell-based model of hemostasis. Thromb Haemost 2001; 85 (06) 958-965
• 56 Tuman KJ, McCarthy RJ, Djuric M, Rizzo V, Ivankovich AD. Evaluation of coagulation during cardiopulmonary bypass with a heparinase-modified thromboelastographic assay. J Cardiothorac Vasc Anesth 1994; 8 (02) 144-149
• 57 Coppell JA, Thalheimer U, Zambruni A. et al. The effects of unfractionated heparin, low molecular weight heparin and danaparoid on the thromboelastogram (TEG): an in-vitro comparison of standard and heparinase-modified TEGs with conventional coagulation assays. Blood Coagul Fibrinolysis 2006; 17 (02) 97-104
• 58 Shinoda T, Arakura H, Katakura M, Shirota T, Nakagawa S. Usefulness of thrombelastography for dosage monitoring of low molecular weight heparin and unfractionated heparin during hemodialysis. Artif Organs 1990; 14 (06) 413-415
• 59 Traverso CI, Caprini JA, Arcelus JI, Arcelus IM. Thromboelastographic modifications induced by intravenous and subcutaneous heparin administration. Semin Thromb Hemost 1995; 21 (Suppl. 04) 53-58
• 60 Dias JD, Lopez-Espina CG, Panigada M, Dalton HJ, Hartmann J, Achneck HE. Cartridge-based thromboelastography can be used to monitor and quantify the activity of unfractionated and low-molecular-weight heparins. TH Open 2019; 3 (03) e295-e305
• 61 Görlinger K, Iqbal J, Dirkmann D, Tanaka KA. Whole blood assay: thromboelastometry. In: Teruya J. ed. Management of Bleeding Patients. Basel: Springer Nature Switzerland AG; 2016: 37
• 62 Van Den Helm S, Yaw HP, Letunica N. et al. Platelet phenotype and function changes with increasing duration of extracorporeal membrane oxygenation. Crit Care Med 2022; 50 (08) 1236-1245
• 63 Goldfarb M, Czer LS, Lam LD, Moriguchi J, Arabia FA, Volod O. High molecular weight von Willebrand factor multimer loss and bleeding in patients with short-term mechanical circulatory support devices: a case series. J Extra Corpor Technol 2018; 50 (02) 77-82
• 64 Cashen K, Meert K, Dalton HJ. Platelet count and function during pediatric extracorporeal membrane oxygenation. Semin Thromb Hemost 2020; 46 (03) 357-365
• 65 Craft RM, Chavez JJ, Bresee SJ, Wortham DC, Cohen E, Carroll RC. A novel modification of the thrombelastograph assay, isolating platelet function, correlates with optical platelet aggregation. J Lab Clin Med 2004; 143 (05) 301-309
• 66 Nelles NJ, Chandler WL. Platelet mapping assay interference due to platelet activation in heparinized samples. Am J Clin Pathol 2014; 142 (03) 331-338
• 67 Giorni C, Costopoulos M, Bachelot-Loza C. et al. Platelet-mapping assay for monitoring antiplatelet therapy during mechanical circulatory support in children: a retrospective observational study. Res Pract Thromb Haemost 2017; 1 (01) 120-127
• 68 Karon BS, Tolan NV, Koch CD. et al. Precision and reliability of 5 platelet function tests in healthy volunteers and donors on daily antiplatelet agent therapy. Clin Chem 2014; 60 (12) 1524-1531
• 69 Chandler WL, Brown AF, Chen D. et al. External quality assurance of platelet function assays: results of the College of American Pathologists Proficiency Testing Program. Arch Pathol Lab Med 2019; 143 (04) 472-482
• 70 Ferguson LP, Duong P, Pearce KF, Murphy P, Biss TT. Monitoring of antiplatelet therapy in children on ventricular assist device support: comparison of Multiplate and Thromboelastography Platelet Mapping. ASAIO J 2019; 65 (01) 84-93
• 71 Volod O, Arabia FA, Lam LD, Runge A, Cheng C, Czer LSC. Platelet mapping by thromboelastography and whole blood aggregometry in adult patients supported by mechanical circulatory support device on aspirin therapy. J Extra Corpor Technol 2020; 52 (01) 13-21
• 72 Mahla E, Suarez TA, Bliden KP. et al. Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study. Circ Cardiovasc Interv 2012; 5 (02) 261-269
• 73 Sivapalan P, Bäck AC, Ostrowski SR, Ravn HB, Johansson PI. Transfusion requirements in elective cardiopulmonary bypass surgery patients: predictive value of multiplate and thromboelastography (TEG) platelet mapping assay. Scand J Clin Lab Invest 2017; 77 (05) 345-351
• 74 Panigada M, E Iapichino G, Brioni M. et al. Thromboelastography-based anticoagulation management during extracorporeal membrane oxygenation: a safety and feasibility pilot study. Ann Intensive Care 2018; 8 (01) 7
• 75 Prakash S, Wiersema UF, Bihari S, Roxby D. Discordance between ROTEM® clotting time and conventional tests during unfractionated heparin-based anticoagulation in intensive care patients on extracorporeal membrane oxygenation. Anaesth Intensive Care 2016; 44 (01) 85-92
• 76 Nair P, Hoechter DJ, Buscher H. et al. Prospective observational study of hemostatic alterations during adult extracorporeal membrane oxygenation (ECMO) using point-of-care thromboelastometry and platelet aggregometry. J Cardiothorac Vasc Anesth 2015; 29 (02) 288-296
• 77 Buscher H, Zhang D, Nair P. A pilot, randomised controlled trial of a rotational thromboelastometry-based algorithm to treat bleeding episodes in extracorporeal life support: the TEM Protocol in ECLS Study (TEMPEST). Crit Care Resusc 2017; 19 (Suppl. 01) 29-36
• 78 Riley JB, Schears GJ, Nuttall GA, Oliver Jr WC, Ereth MH, Dearani JA. Coagulation parameter thresholds associated with non-bleeding in the eighth hour of adult cardiac surgical post-cardiotomy extracorporeal membrane oxygenation. J Extra Corpor Technol 2016; 48 (02) 71-78
• 79 Hellmann C, Schmutz A, Kalbhenn J. Bleeding during veno-venous ECMO cannot reliably be predicted by rotational thrombelastometry (ROTEM™). Perfusion 2018; 33 (04) 289-296
• 80 Laine A, Niemi T, Suojaranta-Ylinen R. et al. Decreased maximum clot firmness in rotational thromboelastometry (ROTEM®) is associated with bleeding during extracorporeal mechanical circulatory support. Perfusion 2016; 31 (08) 625-633
• 81 Popugaev KA, Bakharev SA, Kiselev KV. et al. Clinical and pathophysiologic aspects of ECMO-associated hemorrhagic complications. PLoS One 2020; 15 (10) e0240117
• 82 Chandel A, Desai M, King CS. et al. Agreement between the TEG 6s and TEG 5000 analyzers in extracorporeal membrane oxygenation. ASAIO J 2022; 68 (01) 73-78
• 83 Colman E, Yin EB, Laine G. et al. Evaluation of a heparin monitoring protocol for extracorporeal membrane oxygenation and review of the literature. J Thorac Dis 2019; 11 (08) 3325-3335
• 84 Ranucci M, Baryshnikova E, Isgrò G. et al. Heparin-like effect in postcardiotomy extracorporeal membrane oxygenation patients. Crit Care 2014; 18 (05) 504
• 85 Gilman EA, Koch CD, Santrach PJ, Schears GJ, Karon BS. Fresh and citrated whole-blood specimens can produce different thromboelastography results in patients on extracorporeal membrane oxygenation. Am J Clin Pathol 2013; 140 (02) 165-169
• 86 Chandel A, Patolia S, Looby M, Bade N, Khangoora V, King CS. Association of D-dimer and fibrinogen with hypercoagulability in COVID-19 requiring extracorporeal membrane oxygenation. J Intensive Care Med 2021; 36 (06) 689-695
• 87 Confino E, el-Roeiy A, Friberg J, Gleicher N. The thromboelastogram and circulating lupus anticoagulant. J Reprod Med 1989; 34 (04) 289-291
• 88 Gong H, Shi C, Zhou Z. et al. Evaluating hypercoagulability in new-onset systemic lupus erythematosus patients using thromboelastography. J Clin Lab Anal 2020; 34 (05) e23157
• 89 Nielsen VG. Beyond cell based models of coagulation: analyses of coagulation with clot “lifespan” resistance-time relationships. Thromb Res 2008; 122 (02) 145-152
• 90 Rivard GE, Brummel-Ziedins KE, Mann KG, Fan L, Hofer A, Cohen E. Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography. J Thromb Haemost 2005; 3 (09) 2039-2043
• 91 Stradleigh R, Emerson D, Yaung J. et al. Comparisons of TEG Versus Standard Heparin monitoring Assays in COVID Positive VV ECMO. Paper presented at: Annual International Conference of the American Thoracic Society; May 16, 2022; San Francisco, CA.
• 92 Hranjec T, Estreicher M, Rogers B. et al. Integral use of thromboelastography with platelet mapping to guide appropriate treatment, avoid complications, and improve survival of patients with coronavirus disease 2019-related coagulopathy. Crit Care Explor 2020; 2 (12) e0287
• 93 Bunch CM, Thomas AV, Stillson JE. et al. Preventing thrombohemorrhagic complications of heparinized COVID-19 patients using adjunctive thromboelastography: a retrospective study. J Clin Med 2021; 10 (14) 3097